OTS - Debiopharm and Aspen partner to launch prostate cancer drug Trelstar® in South Africa
2022. February 01. 09:27
Lausanne, Switzerland and Durban, South Africa, 1 February, 2022
(APA/OTS) - Debiopharm (www.debiopharm.com), a Swiss
biopharmaceutical company and Aspen, a South African headquartered
multinational pharmaceutical company announced today their
partnership to launch Trelstar® (Triptorelin) in South Africa for
the treatment of locally advanced and metastatic hormone dependent
prostate cancer. (Trelstar®, a synthetic analogue of GnRH
(Gonadotropin Releasing Hormone) developed by Debiopharm, will be
marketed by Aspen in South Africa.
In 2020, nearly 14,000 South African men were newly diagnosed
with prostate cancer(1) with an average of 5 men dying from the
disease every day.2 In fact, 1 in every 23 South African men will
develop prostate cancer in their lifetime.(2) Trelstar works by
reducing testosterone levels, a hormone essential to prostate
cancer growth. Deprivation of testosterone stops the growth of
hormone dependent prostate cancer, alleviating pain and improving
the quality of life of patients.
We're really enthusiastic to enter into this new alliance with
Aspen, a well-established and trusted pharmaceutical partner for
the commercialization of Trelstar® in South Africa and recognize
the therapeutic benefits that Trelstar® could bring to prostate
cancer patients in this region. Fabrice Paradies, Senior
Director, Business Development & Global Commercial Alliances,
Debiopharm.
Aspen Pharmacare is excited to be able to deliver a world class
oncology product in the treatment of prostate cancer and we are
privileged to partner with Debiopharm to commercialize Trelstar®
within the South African market. We are confident that this product
will add significant benefit to the treatment of prostate cancer.
Neel Andhee-Shah, Head: New Product Development, Aspen Pharmacare.
About Trelstar® (Triptorelin)
Trelstar® (Triptorelin) is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH). Debiopharm has developed
three sustained-release formulations (1, 3 and 6 months) of
Triptorelin Pamoate. First registered in France in 1986,
Triptorelin is currently marketed in more than 80 countries by
Debiopharm's selected partners and is market leader in many
territories worldwide.
About Aspen
Headquartered in Durban, South Africa, Aspen is a partner of
choice as it is a global specialty and branded multinational
pharmaceutical company with a presence in both emerging and
developed markets. Aspen improves the health of patients in more
than 150 countries through its high quality and affordable
medicines. Active at every stage of the value chain, Aspen is
uniquely diversi?ed by geography, product and manufacturing
capability. The Group's key business segments are Manufacturing and
Commercial Pharmaceuticals comprising Regional Brands and Sterile
Focus Brands. For more information, please visit
https://www.aspenpharma.com/
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet
medical needs in oncology and infectious diseases. Bridging the gap
between disruptive discovery products and international patient
reach, we identify high-potential compounds and technologies for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
Visit us www.debiopharm.com/
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Bonine - Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
References
(1.) Globocan 2020;
https://gco.iarc.fr/today/data/factsheets/populations/913-southern-africa-fact-sheets.pdf
(2.) https://mensfoundation.co.za/mens-health/prostate-cancer/
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.